Clinical Trials Logo

Ophthalmopathy clinical trials

View clinical trials related to Ophthalmopathy.

Filter by:

NCT ID: NCT04579458 Withdrawn - Covid19 Clinical Trials

Assessment of COVID-19 in Tearfilm

Start date: December 28, 2020
Phase:
Study type: Observational

To assess the co-relation of COVID-19 in nasopharyngeal swabs and tears or saliva, and to determine duration of COVID-19 activity in ocular fluid and saliva by serial tests over 3 months.

NCT ID: NCT04460001 Recruiting - Ophthalmopathy Clinical Trials

Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for (CRVO)

Start date: May 16, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

To compare the clinical effectiveness of ranibizumab and combination of ranibizumab and triamcinolone for the treatment of macular oedema secondary to CRVO

NCT ID: NCT04387292 Completed - COVID19 Clinical Trials

Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic

SOCOVID
Start date: September 7, 2020
Phase: N/A
Study type: Interventional

Ophthalmologic damages secondary to COVID-19 coronavirus infection are little described. The ocular involvement is probably multiple, ranging from pathologies of the anterior segment such as conjunctivitis and anterior uveitis to disorders that threaten vision such as retinitis or optic neuropathy. On the other hand, in addition to this impairment, when patients are hospitalized for acute respiratory failure, complications related to possible resuscitation, medication prescriptions, positioning and oxygenation. COVID-19 itself, has several components: - An apoptotic action of the viral attack which will generate cellular destruction, whether pulmonary, cardiac or renal or maybe ocular - A secondary autoimmune action with the development of major vascular inflammation, possibly reaching the retinal, choroidal, and optic nerve vessels. A secondary "hyper" inflammatory syndrome with flashing hypercytokinemia and multi-organ decompensation is described in 3,7% to 4 ,3% of severe cases. - A thromboembolic action

NCT ID: NCT03855462 Completed - Ophthalmopathy Clinical Trials

Evaluating Medium-chain Triglycerides as a Temporary Intraocular Tamponading Agent for Retinal Detachment

MCT
Start date: December 17, 2018
Phase: N/A
Study type: Interventional

Background : Surgery is needed in order to flatten and position a detached retina onto the choroid, to allow sealing of the tears and to prevent or reverse vision loss. In case of complex retinal detachment vitrectomies followed by ocular endotamponade - non-solid implants used in ophthalmology - is the most common treatment. Despite several options used by surgeons were not entirely satisfactory, no innovation were marketed in the ocular endotamponade field since decades. Purpose : Regarding comparative physico-chemical properties of medium-chain triglycerides (MCT) with current tamponading agents (silicone oil or gases), it will be proposed to evaluate the MCT as an ocular endotamponade product.

NCT ID: NCT03766737 Completed - Clinical trials for Artificial Intelligence

Validation of the Utility of an Intelligent Visual Acuity Diagnostic System for Children

Start date: May 20, 2018
Phase: N/A
Study type: Interventional

Visual development during early childhood is a vital process. Examining the visual acuity of children is essential for the early detection of visual abnormality, but performing such an assessment in children is challenging. Here, the investigators developed a human-in-the-loop artificial intelligence (AI) paradigm that combines traditional vision examination and AI with integrated software and hardware, thus making the vision examination easy to perform. The investigator also establish a entity intelligent visual acuity diagnostic system based on the paradigm, and conduct clinical trial to validate if the diagnostic system can offsetting the shortcomings of human doctors.

NCT ID: NCT03611387 Recruiting - Ophthalmopathy Clinical Trials

Artificial Intelligence Screening on Patients With Primary Angle Closure Glaucoma

AI
Start date: April 1, 2018
Phase:
Study type: Observational [Patient Registry]

The Tomey CASIA (Tomey Corporation, Nagoya, Japan) is a novel rapid imaging device that captures high-quality imaging of the entire anterior chamber of the eye over detailed imaging of a single section. In this prospective study, we want to investigate and compare the anatomical structure of the drainage angle of the eye in patients with different types glaucoma using Tomey machine. This study gives us a better understanding of the predictability, validity and accuracy of Tomey machine in the diagnosis of different types of glaucoma. Moreover, the data collected here will be used to create an artificial intelligence (AI) platform to screen certain type of glaucoma.

NCT ID: NCT03499145 Completed - Clinical trials for Artificial Intelligence

Validation of the Utility of Ophthalmology Intelligent Diagnostic System

Start date: April 1, 2018
Phase:
Study type: Observational

The prevention and treatment of diseases via artificial intelligence represents an ultimate goal in computational medicine. Application scenarios of the current medical algorithms are too simple to be generally applied to real-world complex clinical settings. Here, the investigators use "deep learning" and "visionome technique", an novel annotation method for artificial intelligence in medical, to create an automatic detection and classification system for four key clinical scenarios: 1) mass screening, 2) comprehensive clinical triage, 3) hyperfine diagnostic assessment, and 4) multi-path treatment planning. The investigator also establish a telemedicine system and conduct clinical trial and website-based study to validate its versatility.

NCT ID: NCT03492242 Completed - Cancer Clinical Trials

Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction

CHIMeRA
Start date: February 1, 2018
Phase:
Study type: Observational

Immune checkpoint inhibitors (ICIs) might have high grade immune-related adverse events (irAEs) from rhumatologic, endocrinologic, cardiac or other system origin. This study investigates reports of drug induced irAEs with treatment including anti-PD1, Anti-PDL-1, and Anti-CTLA4 classes using the World Health Organization (WHO) database VigiBase and the french database Base Nationale de PharmacoVigilance (BNPV).